Last reviewed · How we verify
DTaP IPV HB PRP~T vaccine
This pentavalent vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b.
This pentavalent vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b. Used for Prevention of diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and Haemophilus influenzae type b infection in infants and children.
At a glance
| Generic name | DTaP IPV HB PRP~T vaccine |
|---|---|
| Sponsor | Sanofi Pasteur, a Sanofi Company |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
DTaP IPV HB PRP~T is a combination vaccine containing inactivated toxoids (diphtheria and tetanus), acellular pertussis antigens, inactivated poliovirus, hepatitis B surface antigen, and polyribosylribitol phosphate conjugate from H. influenzae type b. Upon administration, these antigens trigger both humoral (antibody) and cell-mediated immune responses, providing protection against these five serious infectious diseases.
Approved indications
- Prevention of diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and Haemophilus influenzae type b infection in infants and children
Common side effects
- Injection site pain, redness, or swelling
- Fever
- Irritability or fussiness
- Drowsiness
- Loss of appetite
- Vomiting
Key clinical trials
- Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (PHASE3)
- Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (PHASE3)
- Post-marketing Surveillance Study for the Safety of a DTaP-IPV- HB-PRP~T Vaccine in Republic of Korea
- Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa (PHASE3)
- Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants (PHASE1, PHASE2)
- Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the Russian Federation and Mexico (PHASE3)
- DTaP-IPV-HB-PRP-T Combined Vaccine as a Primary Series and a Second Year of Life Booster in HIV-Exposed Infected and Uninfected Infants (PHASE3)
- Immunogenicity and Safety of Sanofi Pasteur's Combined Vaccine Given as a Three-Dose Primary Series at 2, 3,4 Months of Age and Followed by a Booster Dose Given at 16 to 17 Months of Age in Vietnamese Infants Who Previously Received a Dose of Hepatitis B Vaccine at Birth or Within 1 Week After Birth (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DTaP IPV HB PRP~T vaccine CI brief — competitive landscape report
- DTaP IPV HB PRP~T vaccine updates RSS · CI watch RSS
- Sanofi Pasteur, a Sanofi Company portfolio CI